Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 6—June 2026

Research

Antimicrobial-Resistant Neisseria gonorrhoeae of Public Health Concern, New South Wales, Australia, 2022–2024

Liz J. Walker1Comments to Author , Sebastiaan J. Van Hal1, Cecilia Li, Steven J. Nigro, Ellen Donnan, Nathan Ryder, Monica Lahra2, and Janaki Amin2
Author affiliation: NSW Health, St. Leonards, New South Wales, Australia (L.J. Walker, C. Li, S.J. Nigro, E. Donnan, N. Ryder, J. Amin); Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (S.J. van Hal); The University of Sydney Central Clinical School, Sydney (S.J. van Hal); The University of Sydney Institute for Infectious Diseases, Sydney (E. Donnan); Prince of Wales Hospital and Community Health Services, Randwick, New South Wales, Australia (M.M. Lahra); University of New South Wales, Sydney (M.M. Lahra); Macquarie University, Sydney (J. Amin)

Main Article

Figure 2

Phylogenetic tree and antimicrobial resistance network analysis from study of antimicrobial-resistant Neisseria gonorrhoeae of public health concern, New South Wales, Australia, 2022–2024. A) Phylogenetic tree and isolate data. Ninety-three of the 94 isolates met the quality mapping criteria. B) Network analysis of cases with high-level resistance to azithromycin, with nodes colored according to acquisition source. C) Network analysis of cases with decreased susceptibility to ceftriaxone, with nodes colored according to acquisition source. Azi, azithromycin; CRO, ceftriaxone; DS, decreased susceptibility; HLR, high-level resistance; MLST, multilocus sequence type.

Figure 2. Phylogenetic tree and antimicrobial resistance network analysis from study of antimicrobial-resistant Neisseria gonorrhoeae of public health concern, New South Wales, Australia, 2022–2024. A) Phylogenetic tree and isolate data. Ninety-three of the 94 isolates met the quality mapping criteria. B) Network analysis of cases with high-level resistance to azithromycin, with nodes colored according to acquisition source. C) Network analysis of cases with decreased susceptibility to ceftriaxone, with nodes colored according to acquisition source. Azi, azithromycin; CRO, ceftriaxone; DS, decreased susceptibility; HLR, high-level resistance; MLST, multilocus sequence type.

Main Article

1These first authors contributed equally to this article.

2These joint senior authors contributed equally to this article.

Page created: April 30, 2026
Page updated: May 20, 2026
Page reviewed: May 20, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external